secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2023-05-17T23:59:59+00:00
Accession:  0001601830-23-000027
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion appoints CMO David Mauro; completes Valence acquisition for up to ~8.1M shares
--------------------------------------------------------------------------------

- David Mauro appointed CMO effective June 1; brings 20+ years oncology drug development experience from Codiak, Checkmate, Prelude, Advaxis.
- Acquisition of Valence Discovery completed; consideration includes up to ~2.2M Class A shares and ~5.9M exchangeable shares.
- Recursion assumes Valence options exercisable for up to ~0.8M Class A shares; total potential dilution up to ~8.9M shares.
- Dr. Mauro will lead Recursion's five clinical programs and growing pre-clinical pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/0001601830-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183023000027/rxrx-20230516.htm
  HTML page:      https://secwatch.observer/filing/0001601830-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer